- Company
- Keytruda-Renvima has been approved as the primary treatment
- by Jan 12, 2022 06:05am
- MSD Korea announced on the 11th that a combination therapy of anti-PD-1 immuno-cancer drug Keytruda (Pembrolizumab) and Lenvima (Lenvatinib) has been approved by the MFDS as the primary treatment for advanced new cell carcinoma. Combination therapy of Keytruda and Lenvima in renal cell cancer treatment recorded 23.9 months of mPFS and impr
- Opinion
- [Reporter’s View] Can companies get EUAs as they promised?
- by Lee, Tak-Sun Jan 12, 2022 06:04am
- The Emergency Use Authorization (EUA) system was first introduced to Korea in March last year. AstraZeneca’s COVID-19 vaccine manufactured in Italy, Moderna’s COVID-19 vaccine manufactured by Samsung Biologics, Pfizer’s oral COVID-19 treatment Paxlovid, and the COVID-19 injection Remdesivir for use in patients under 15 were approved using Kor
- Company
- Reducing # of sales positions of pharmaceutical companies
- by Moon, sung-ho Jan 12, 2022 06:04am
- It was found that the number of personnel engaged in the control and bio industries has steadily increased over the report showed. However, amid the boom in pharmaceuticals and bio, the position of sales workers is decreasing day by day. Analysts say this is because it is concentrated on the development of online sales and marketing and contract
- Product
- The gov is pushing to supply COVID-19 PO tx with pharmacies
- by Kang, Shin-Kook Jan 12, 2022 06:04am
- The government is taking full-fledged steps to supply COVID-19 PO treatment to pharmacies. The Central Disaster and Safety Counters Headquaters (CDSCHQ) will hold an online meeting this afternoon (10th) with drug organizations participating and discuss oral corona treatment prescriptions and dispensing. In other words, the direction of the CD
- Company
- Pharmaceutical bio jobs to be reorganized
- by Chon, Seung-Hyun Jan 12, 2022 06:04am
- Jobs in the pharmaceutical bio industry have increased by more than 50% in the past nine years. The number of production workers surged. In recent years, it is analyzed that many jobs have been created in production jobs as pharmaceutical bio companies have greatly increased production facilities and expanded their CMO business. The proportion o
- Company
- Soliris at risk of price cuts amid increasing PA rejections
- by Moon, sung-ho Jan 12, 2022 06:04am
- The National Health Insurance Service has selected ‘Soliris (eculizumab)’ as a ‘subject for PVA monitoring’ and began monitoring its claims amount, believing that its use has increased over a certain level. However, all of the prior authorization applications for the same drug had been rejected last month. In other words, the drug is doub
- Company
- Ultra-high-priced ‘Kymriah’ is up for DREC deliberations
- by Eo, Yun-Ho Jan 11, 2022 06:29am
- Whether the new CAR-T therapy ‘Kymriah’ will be applied insurance benefit is receiving wide attention. According to industry sources, the world’s first chimeric antigen receptor T-cell (CAR-T) therapy ‘Kymriah' will be deliberated as an agenda by the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Commi
- Policy
- Lee wants to cover infertility, contraception, HPV vaccines
- by Lee, Jeong-Hwan Jan 11, 2022 06:29am
- With the rising heat over the insurance coverage of hair loss treatments that was mentioned by presidential candidate Jae-Myn Lee, other healthcare-related election pledges made by the presidential candidates are also being reilluminated. Lee, who is planning to publically announce his pledge promising the insurance coverage of hair loss trea
- Policy
- Alopecia belongs to the health sector, benefits are possible
- by Lee, Jeong-Hwan Jan 11, 2022 06:29am
- Democratic Party of Korea's presidential candidate Lee Jae-myung claimed that the application of health insurance for hair loss treatments is a health pledge to alleviate public pain, and said he is reviewing the targets, ratios, and amounts through experts in the camp. He said that if pain relief is possible at an annual cost of around 10
- Policy
- 22 companies' Dapagliflozin+Sitaglipin were approved
- by Lee, Tak-Sun Jan 11, 2022 06:28am
- DongKoo Bio has obtained a number of drugs that are the same as the new diabetes drug "Dapagliflozin+Sitagliptin" approved on the 23rd of last month. A large number of consignment items produced by Dongkoo Bio have entered. Dapagliflozin+Sitaglipin is a new combination complex that has never been released before, but competition has become i
